The Future of Psychedelics

At JAS, as Matthias mentioned, we don't invest in traditional therapeutic companies. We do have both a health care and a tech driven biology bucket vertical. For those companies looking for a mix, both of folks who are deep in the science understand the policy,. As more of a generalist fund, we want to see a team that understands product market.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app